Revolutionizing Breast Cancer Treatment: The DEBRA Trial and MammaPrint’s Role

Agendia, Inc. is thrilled to announce the enrollment of the first patient in the DEBRA Trial, leveraging MammaPrint® for a groundbreaking study aimed at optimizing breast cancer treatment. This initiative represents a pivotal shift towards personalized healthcare, emphasizing the need for a nuanced approach to breast cancer management.

Unlocking Personalized Treatment Pathways with MammaPrint®

The DEBRA Trial, a Phase III study conducted by NRG Oncology, seeks to evaluate the potential of de-escalating radiation therapy in specific breast cancer cases. Utilizing the MammaPrint 70-gene signature, this research focuses on individuals with Stage I, hormone-sensitive, HER2-Negative breast cancer, offering new hope for less invasive treatment options.

Challenging Conventional Treatment Through Innovation

Under the guidance of experts like Dr. Eric Brown and Dr. Vito Antonucci, the DEBRA Trial explores alternative, tailored treatment strategies that prioritize patient well-being and quality of life. By questioning the necessity of radiation post-lumpectomy, Agendia aims to redefine breast cancer care standards.

The Crucial Role of Early Detection and Genomic Profiling

MammaPrint’s application in the DEBRA trial underscores the importance of early detection and precise risk assessment in breast cancer treatment. Through detailed genomic profiling, Agendia seeks to empower patients and clinicians with actionable insights, facilitating informed decision-making and fostering optimal outcomes.

Empowering Patients and Advancing Care with Learn Look Locate

At Learn Look Locate, we are committed to supporting patients throughout their breast cancer journey. By highlighting initiatives like the DEBRA Trial and the significance of MammaPrint, we aim to empower individuals with the knowledge and resources necessary for navigating their treatment.